Truseltiq

Generic name:infigratinib
Dosage form: capsules
Drug class:Multikinase inhibitors

Medically reviewed by Judith Stewart, BPharm. Last updated on May 31, 2022.

What is Truseltiq?

Truseltiq is a prescription medicine used to treat adults with bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed by surgery:

• who have already received a previous treatment, and
• whose tumor has a certain type of abnormal “FGFR2” gene.

Your healthcare provider will test your cancer for certain FGFR2 gene abnormalities to make sure that Truseltiq is right for you.
It is not known if this medicine is safe and effective in children.

Before taking Truseltiq

Before you start treatment, tell your healthcare provider about all your medical conditions, including if you:

• have vision or eye problems
• have kidney problems
• have liver problems
• are pregnant or plan to become pregnant. Truseltiq can harm your unborn baby or cause loss of your pregnancy (miscarriage). You should not become pregnant during treatment.

Females who can become pregnant:

• • Your healthcare provider should do a pregnancy test before you start treatment.
  • You should use effective birth control during treatment and for 1 month after your final dose.
    Talk to your healthcare provider about birth control methods that may be right for you during this time.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during this time.

Males with female partners who can become pregnant:

• • You should use effective birth control when sexually active during treatment, and for 1 month after your final dose.
  • are breastfeeding or plan to breastfeed. It is not known if Truseltiq passes into your breast.